Shahinaz Gadalla

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3954433/publications.pdf

Version: 2024-02-01

135 papers	3,682 citations	147801 31 h-index	161849 54 g-index
140 all docs	140 docs citations	140 times ranked	6085 citing authors

#	Article	IF	Citations
1	Survival Modelling for Data From Combined Cohorts: Opening the Door to Meta Survival Analyses and Survival Analysis Using Electronic Health Records. International Statistical Review, 2023, 91, 72-87.	1.9	1
2	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
3	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances, 2022, 6, 339-357.	5.2	35
4	HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. Blood, 2022, 139, 1452-1468.	1.4	52
5	Menopausal hormone therapy and risk of biliary tract cancers. Hepatology, 2022, 75, 309-321.	7.3	9
6	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 310-320.	1.2	11
7	Telomere length and epigenetic clocks as markers of cellular aging: a comparative study. GeroScience, 2022, 44, 1861-1869.	4.6	18
8	Genetic testing in severe aplastic anemia is required forÂoptimal hematopoietic cell transplant outcomes. Blood, 2022, 140, 909-921.	1.4	18
9	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplantation and Cellular Therapy, 2022, 28, 712.e1-712.e8.	1.2	3
10	Comparison of total body irradiation <i>versus</i> non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica, 2021, 106, 1839-1845.	3.5	13
11	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplantation and Cellular Therapy, 2021, 27, 142.e1-142.e11.	1.2	3
12	Method comparison studies of telomere length measurement using qPCR approaches: A critical appraisal of the literature. PLoS ONE, 2021, 16, e0245582.	2.5	43
13	Measurement of Telomere Length for Longitudinal Analysis: Implications of Assay Precision. American Journal of Epidemiology, 2021, 190, 1406-1413.	3.4	28
14	Epigenetic Aging and Hematopoietic Cell Transplantation in Patients With Severe Aplastic Anemia. Transplantation and Cellular Therapy, 2021, 27, 313.e1-313.e8.	1.2	8
15	Drug-Wide Association Study (DWAS): Challenges and Opportunities. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 597-599.	2.5	1
16	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 410-422.	1.2	13
17	Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study. PLoS Medicine, 2021, 18, e1003615.	8.4	38
18	DNA-methylation-based telomere length estimator: comparisons with measurements from flow FISH and qPCR. Aging, 2021, 13, 14675-14686.	3.1	11

#	Article	IF	Citations
19	Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia. Scientific Reports, 2021, 11, 15004.	3.3	4
20	Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2021, 39, 2397-2409.	1.6	19
21	Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation. Transplantation and Cellular Therapy, 2021, 27, 926.e1-926.e10.	1.2	2
22	Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients postâ€“unrelated HCT. Blood Advances, 2021, 5, 66-70.	5.2	6
23	Whole Exome Sequencing in Severe Aplastic Anemia Identifies Unrecognized Inherited Subset with Inferior Survival after Hematopoietic Cell Transplant. Blood, 2021, 138, 605-605.	1.4	0
24	Germline-Somatic Interactions in Myelofibrosis Susceptibility. Blood, 2021, 138, 313-313.	1.4	0
25	Preâ€transplant short telomeres are associated with high mortality risk after unrelated donor haematopoietic cell transplant for severe aplastic anaemia. British Journal of Haematology, 2020, 188, 309-316.	2.5	9
26	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. Biology of Blood and Marrow Transplantation, 2020, 26, 472-479.	2.0	21
27	The role of 5Î±â€reductase inhibitors in gastroâ€oesophageal cancer risk: A nested caseâ€control study. Pharmacoepidemiology and Drug Safety, 2020, 29, 48-56.	1.9	4
28	Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study. Annals of Clinical and Translational Neurology, 2020, 7, 126-131.	3.7	4
29	Diabetes, metformin and cancer risk in myotonic dystrophy type I. International Journal of Cancer, 2020, 147, 785-792.	5.1	13
30	Comparison of outcomes of HCT in blast phase of BCR-ABL1â^' MPN with de novo AML and with AML following MDS. Blood Advances, 2020, 4, 4748-4757.	5.2	14
31	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2020, 26, 2139-2146.	2.0	14
32	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e715-e723.	4.6	8
33	Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. Breast Cancer Research and Treatment, 2020, 184, 543-558.	2.5	6
34	Survival following allogeneic transplant in patients with myelofibrosis. Blood Advances, 2020, 4, 1965-1973.	5.2	63
35	Incidence, Risk Factors for and Outcomes of Transplantâ€Associated Thrombotic Microangiopathy. British Journal of Haematology, 2020, 189, 1171-1181.	2.5	58
36	Population Frequency of Fanconi Pathway Gene Variants and Their Association with Survival After Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2020, 26, 817-822.	2.0	6

#	Article	IF	Citations
37	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. American Journal of Human Genetics, 2020, 106, 264-271.	6.2	25
38	Prognostic Impact of Pre-Transplant Chromosomal Aberrations Detected By SNP-Array in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplant for Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2020, 26, S12-S13.	2.0	0
39	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
40	Telomere length in hematopoietic cell transplant. Blood, 2020, 136, 2972-2973.	1.4	0
41	Chromosomal Aberrations in Pre-HCT Blood Samples and Outcomes after Transplantation in Patients with Myelofibrosis. Blood, 2020, 136, 4-5.	1.4	0
42	Pre-Transplant Clonal Mosaicism Is Associated with Increased Relapse and Lower Survival in Acute Lymphoblastic Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplant. Blood, 2020, 136, 9-10.	1.4	0
43	Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching. Blood, 2020, 136, 24-26.	1.4	0
44	Survival patterns and cancer determinants in families with myotonic dystrophy type 1. European Journal of Neurology, 2019, 26, 58-65.	3.3	9
45	Association Between Aspirin Use and Biliary Tract Cancer Survival. JAMA Oncology, 2019, 5, 1802.	7.1	23
46	Benign tumors in myotonic dystrophy type I target diseaseâ€related cancer sites. Annals of Clinical and Translational Neurology, 2019, 6, 1510-1518.	3.7	16
47	Reproductive Cancer Risk Factors in Women With Myotonic Dystrophy (DM): Survey Data From the US and UK DM Registries. Frontiers in Neurology, 2019, 10, 1071.	2.4	5
48	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1875-1883.	2.0	14
49	Clinico-pathologic and mammographic characteristics of inflammatory and non-inflammatory breast cancer at six centers in North Africa. Breast Cancer Research and Treatment, 2019, 176, 407-417.	2.5	10
50	Survival Trends in Infants Undergoing Allogeneic Hematopoietic Cell Transplant. JAMA Pediatrics, 2019, 173, e190081.	6.2	14
51	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Advances, 2019, 3, 1441-1449.	5.2	12
52	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
53	Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder. ERJ Open Research, 2019, 5, 00209-2019.	2.6	13
54	Statin use and reduced risk of biliary tract cancers in the UK Clinical Practice Research Datalink. Gut, 2019, 68, 1458-1464.	12.1	23

#	Article	IF	Citations
55	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 480-487.	2.0	10
56	Benefits of combining prevalent and incident cohorts: An application to myotonic dystrophy. Statistical Methods in Medical Research, 2019, 28, 3333-3345.	1.5	9
57	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biology of Blood and Marrow Transplantation, 2019, 25, 270-278.	2.0	21
58	De Novo and Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome: Similarities and Differences in SNP-Array Detected Chromosomal Aberrations in Pre-Transplant Blood Samples. Blood, 2019, 134, 1430-1430.	1.4	2
59	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. Blood, 2019, 134, 1224-1224.	1.4	0
60	Risk factors for Burkitt lymphoma: a nested caseâ€control study in the <scp>UK</scp> Clinical Practice Research Datalink. British Journal of Haematology, 2018, 181, 505-514.	2.5	11
61	Donor telomere length and causes of death after unrelated hematopoietic cell transplantation in patients with marrow failure. Blood, 2018, 131, 2393-2398.	1.4	15
62	Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population. Breast Cancer Research and Treatment, 2018, 169, 607-614.	2.5	7
63	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplantation, 2018, 53, 932-937.	2.4	1
64	No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. Bone Marrow Transplantation, 2018, 53, 383-391.	2.4	13
65	Benign and malignant tumors in the UK myotonic dystrophy patient registry. Muscle and Nerve, 2018, 57, 316-320.	2.2	15
66	Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the <scp>U</scp>.<scp>K</scp>. <scp>C</scp>linical <scp>P</scp>ractice <scp>R</scp>esearch <scp>D</scp>atalink. International Journal of Cancer, 2018, 142, 1174-1181.	5.1	25
67	Autoimmune diseases and breast cancer risk by tumor hormoneâ€receptor status among elderly women. International Journal of Cancer, 2018, 142, 1202-1208.	5.1	18
68	Survival Trends after Allogeneic Hematopoietic Cell Transplant (HCT) in Children Less Than One-Year-Old (Infants). Biology of Blood and Marrow Transplantation, 2018, 24, S116.	2.0	0
69	Prevalence of pathogenic/likely pathogenic variants in the 24 cancer genes of the ACMG Secondary Findings v2.0 list in a large cancer cohort and ethnicity-matched controls. Genome Medicine, 2018, 10, 99.	8.2	15
70	Cancer Risk in Myotonic Dystrophy Type I: Evidence of a Role for Disease Severity. JNCI Cancer Spectrum, 2018, 2, pky052.	2.9	24
71	The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature. Journal of the National Cancer Institute, 2018, 110, 1048-1058.	6.3	24
72	Telomere Length Calibration from qPCR Measurement: Limitations of Current Method. Cells, 2018, 7, 183.	4.1	23

#	Article	IF	Citations
73	Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurology: Clinical Practice, 2018, 8, 507-520.	1.6	115
74	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. Blood Advances, 2018, 2, 2922-2936.	5.2	35
75	Similar telomere attrition rates in androgen-treated and untreated patients with dyskeratosis congenita. Blood Advances, 2018, 2, 1243-1249.	5.2	30
76	Clonal Alterations and Survival after Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2018, 24, S119-S120.	2.0	3
77	Cancer phenotype in myotonic dystrophy patients: Results from a metaâ€analysis. Muscle and Nerve, 2018, 58, 517-522.	2.2	22
78	Chromosomal Aberrations and Survival after Unrelated Donor Hematopoietic Stem Cell Transplant in Patients with Fanconi Anemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2003-2008.	2.0	9
79	Abstract 1237: Cancer risk in myotonic dystrophy type I: First evidence of a role for disease severity. , 2018, , .		0
80	Donor IFNL4 Genotype Is Associated with Transplant-Related Mortality after Unrelated Donor Myeloablative Hematopoietic Cell Transplantation in Patients with Acute Leukemia. Blood, 2018, 132, 968-968.	1.4	0
81	Diabetes, Abnormal Glucose, Dyslipidemia, Hypertension, and Risk of Inflammatory and Other Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 862-868.	2.5	25
82	Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow Transplant Research Report. Biology of Blood and Marrow Transplantation, 2017, 23, 1342-1349.	2.0	50
83	Relative Telomere Length before Hematopoietic Cell Transplantation and Outcome after Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 1054-1058.	2.0	9
84	Pigmentation phenotype, photosensitivity and skin neoplasms in patients with myotonic dystrophy. European Journal of Neurology, 2017, 24, 713-718.	3.3	13
85	Editorial: US Cancer Statistics of Survival: Achievements, Challenges, and Future Directions. Journal of the National Cancer Institute, 2017, 109, .	6.3	6
86	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Subsequent Neoplasms Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 367-378.	2.0	50
87	Correlation of Leukocyte Telomere Length Measurement Methods in Patients with Dyskeratosis Congenita and in Their Unaffected Relatives. International Journal of Molecular Sciences, 2017, 18, 1765.	4.1	42
88	Effect of pre-analytic variables on the reproducibility of qPCR relative telomere length measurement. PLoS ONE, 2017, 12, e0184098.	2.5	55
89	Telomeres and the natural lifespan limit in humans. Aging, 2017, 9, 1130-1142.	3.1	82
90	The limitations of qPCR telomere length measurement in diagnosing dyskeratosis congenita. Molecular Genetics & Genomic Medicine, 2016, 4, 475-479.	1.2	20

#	Article	IF	Citations
91	Effect of Recipient Age and Stem Cell Source on the Association between Donor Telomere Length and Survival after Allogeneic Unrelated Hematopoietic Cell Transplantation for Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2016, 22, 2276-2282.	2.0	22
92	Brain tumors in patients with myotonic dystrophy: a populationâ€based study. European Journal of Neurology, 2016, 23, 542-547.	3.3	14
93	Increased risk of tumor in DM1 is not related to exposure to common lifestyle risk factors. Journal of Neurology, 2016, 263, 492-498.	3.6	32
94	Donor Telomere Length and Outcomes after Allogeneic Unrelated Hematopoietic Cell Transplant in Patients with Acute Leukemia. Blood, 2016, 128, 520-520.	1.4	1
95	Germline Mutations in Patients Receiving Unrelated Donor Hematopoietic Cell Transplant for Severe Aplastic Anemia. Blood, 2016, 128, 68-68.	1.4	0
96	Polychlorinated Biphenyls and Cancer: Are Telomeres to Blame?. EBioMedicine, 2015, 2, 1856-1857.	6.1	1
97	Association Between Donor Leukocyte Telomere Length and Survival After Unrelated Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia. JAMA - Journal of the American Medical Association, 2015, 313, 594.	7.4	73
98	Increasing Incidence of Chronic Graft-versus-Host Disease inÂAllogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2015, 21, 266-274.	2.0	331
99	Pesticide Use and Relative Leukocyte Telomere Length in the Agricultural Health Study. PLoS ONE, 2015, 10, e0133382.	2.5	42
100	NHANES III equations enhance early detection and mortality prediction of bronchiolitis obliterans syndrome after hematopoietic SCT. Bone Marrow Transplantation, 2014, 49, 561-566.	2.4	9
101	Telomeres in Molecular Epidemiology Studies. Progress in Molecular Biology and Translational Science, 2014, 125, 113-131.	1.7	23
102	Donor Telomere Length Predicts Recipient Survival after Allogeneic Hematopoietic Cell Transplantation in Patients with Bone Marrow Failure Syndromes. Biology of Blood and Marrow Transplantation, 2014, 20, S33-S34.	2.0	0
103	Abstract 5100: Development of a direct-measurement molecular assay to determine telomere length in human samples. Cancer Research, 2014, 74, 5100-5100.	0.9	1
104	Telomere length and risk of glioma. Cancer Epidemiology, 2013, 37, 935-938.	1.9	28
105	The Long and Short of Telomeres and Cancer Association Studies. Journal of the National Cancer Institute, 2013, 105, 448-449.	6.3	25
106	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. Biology of Blood and Marrow Transplantation, 2013, 19, 1238-1243.	2.0	108
107	Bclâ€2 level as a biomarker for 13q14 deletion in CLL. Cytometry Part B - Clinical Cytometry, 2013, 84B, 237-247.	1.5	12
108	Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. PLoS ONE, 2013, 8, e79851.	2.5	23

#	Article	IF	Citations
109	Correlates of tumor development in patients with myotonic dystrophy. Journal of Neurology, 2012, 259, 2161-2166.	3.6	38
110	Enhancing a Cancer Prevention and Control Curriculum Through Interactive Group Discussions. Journal of Cancer Education, 2012, 27, 428-435.	1.3	0
111	The relationship between DNA methylation and telomere length in dyskeratosis congenita. Aging Cell, 2012, 11, 24-28.	6.7	28
112	Telomere biology in hematopoiesis and stem cell transplantation. Blood Reviews, 2011, 25, 261-269.	5.7	39
113	Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia. Journal of Viral Hepatitis, 2011, 18, 161-169.	2.0	12
114	A populationâ€based assessment of mortality and morbidity patterns among patients with thymoma. International Journal of Cancer, 2011, 128, 2688-2694.	5.1	59
115	Cancer Risk Among Patients With Myotonic Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2011, 306, 2480-6.	7.4	99
116	Patient Understanding of Diabetes Self-Management: Participatory Decision-Making in Diabetes Care. Journal of Diabetes Science and Technology, 2011, 5, 723-730.	2.2	18
117	LINE-1 methylation is inherited in familial testicular cancer kindreds. BMC Medical Genetics, 2010, 11, 77.	2.1	55
118	Telomere length in blood, buccal cells, and fibroblasts from patients with inherited bone marrow failure syndromes. Aging, 2010, 2, 867-874.	3.1	120
119	Risks of myeloid malignancies in patients with autoimmune conditions. British Journal of Cancer, 2009, 100, 822-828.	6.4	222
120	Breast cancer risk in elderly women with systemic autoimmune rheumatic diseases: a population-based caseâ€“control study. British Journal of Cancer, 2009, 100, 817-821.	6.4	48
121	Populationâ€based study of autoimmune conditions and the risk of specific lymphoid malignancies. International Journal of Cancer, 2009, 125, 398-405.	5.1	221
122	Evidence-based care for breast cancer survivors: Communicating the Institute of Medicine Guidelines in medical practice. Patient Education and Counseling, 2009, 77, 413-420.	2.2	15
123	Cancer Risk Assessment for the Primary Care Physician. Primary Care - Clinics in Office Practice, 2009, 36, 471-488.	1.6	6
124	Correlation of Telomere Length in Blood, Buccal Cells, and Fibroblasts From Patients with Inherited Bone Marrow Failure Syndromes.. Blood, 2009, 114, 1083-1083.	1.4	4
125	Multimodal Bcl-2 Sub-Populations in CLL.. Blood, 2009, 114, 4391-4391.	1.4	0
126	Exploring Patient-Physician Communication in Breast Cancer Care for African American Women Following Primary Treatment. Oncology Nursing Forum, 2008, 35, 836-843.	1.2	68

#	Article	IF	Citations
127	Hematopoietic Malignancies Associated with Viral and Alcoholic Hepatitis. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3069-3075.	2.5	100
128	Evaluation of serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C. Journal of Hepatology, 2007, 46, 620-627.	3.7	50
129	Oral cancer exams among cigarette smokers in Maryland. Cancer Detection and Prevention, 2006, 30, 499-506.	2.1	13
130	Family Perspectives on Communication With Healthcare Providers During End-of-Life Cancer Care. Oncology Nursing Forum, 2006, 33, 753-760.	1.2	59
131	Readers respond to "balancing evidence-based medicine and cultural competence in the quest to end healthcare disparities". MedGenMed: Medscape General Medicine, 2006, 8, 73; author reply 24.	0.2	0
132	Nicotine dependance among adult male smokers in rural Egypt. Journal of the Egyptian Society of Parasitology, 2003, 33, 1019-30.	0.2	6
133	Prevalence of smoking among rural secondary school students in Qualyobia governorate. Journal of the Egyptian Society of Parasitology, 2003, 33, 1031-50.	0.2	25
134	Water pipe (Sisha) smoking in cafes in Egypt. Journal of the Egyptian Society of Parasitology, 2003, 33, 1073-85.	0.2	24
135	A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation. Blood, 0, , .	1.4	9